At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02142 HBM HOLDINGS-B
Market Closed 12-12 16:08:09
13.440
+0.080
+0.60%
High13.540
Low13.100
Vol3.51M
Open13.540
D1 Closing13.360
Amplitude3.29%
Mkt Cap11.70B
Tradable Cap11.70B
Total Shares870.56M
T/O46.63M
T/O Rate0.40%
Tradable Shares870.56M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
HBM Holdings Repurchases 200,000 Shares at HK$13.65 Each in HKEX Filing
Hbm Holdings Ltd is an investment holding company mainly engaged in the business of developing therapeutics in the fields of immuno-oncology and immunology diseases. The Company's products include HBM9161, HBM4003, HBM7008 and HBM1020. Batoclimab (HBM9161) is mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD). Tanfanercept (HBM9036) is mainly used for dry eye disease (DED). The Company also researches and develops immuno-oncology portfolio, including internally developed next generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors. The Company owns Harbour Mice Platform, generating fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 format as well as heavy chain only (HCAb) format.